Eli Lilly, the maker of Zepbound®, announced that they plan to investigate their glucagon-like peptide-1 (GLP-1) receptor agonist in clinical trials for alcohol and drug addiction.
After the overwhelming success of GLP-1 agonists in the diabetes and obesity space, can we expect the same for substance use disorders (SUDs)?
GLP-1 agonists are a class of drugs originally developed to treat type 2 diabetes and, more recently, obesity. There is also considerable evidence that reductions in craving can be achieved in addictive disorders. In this article, Alcimed explores the progress of GLP-1 agonist development, and the evolving landscape of SUDs.
Want to know more? 👉
🎬 Subscribe to our YouTube channel!
🌐 Follow us for more expeditions:
Linkedin:
Our website:
🧭 About Alcimed:
We help both private and public decision-makers exploring and developing uncharted territories, dealing with new technologies, new offers, new geographies, possible futures, and new ways to innovate. Today, we are a team of 220 explorers spread over 8 offices (in France, Europe, USA and Singapore). Our dream? To build a team of 1000 explorers!
🔍 Have a project? Contact our explorers 👇
🚀 Want to climb aboard? 👉
00:00 Intro
00:27 What can GLP-1 do exactly?
1:37 The actual and future GLP-1agonists market
2:19 Drawbacks and side effects of GLP-1 agonists
2:37 Conclusion
source
